TITLE

More Positive Data for CF Drug; Vertex Eyes 2H11 NDA

PUB. DATE
April 2011
SOURCE
Bioworld Week;4/4/2011, Vol. 19 Issue 14, p3
SOURCE TYPE
Periodical
DOC. TYPE
Article
ABSTRACT
The article reports on a positive data for cystic fibrosis (CF) drug VX-770 in adult patients as well as the revelation of a study by Vertex Pharmaceuticals Inc. which involves 6 to 11 aged children that shows a good trend towards support on the proposed new drug application (NDA).
ACCESSION #
60167018

 

Related Articles

  • Vertex CF Results Positive, But No Home Run.  // Bioworld Week;6/13/2011, Vol. 19 Issue 24, p5 

    The article reports that the phase two trial conducted by Vertex Pharmaceuticals Inc. involving the combination of two drugs for cystic fibrosis (CF) had shown positive interim results but these are not viewed as home run.

  • Excitement mounts for first disease-modifying cystic fibrosis drugs. Opar, Alisa // Nature Reviews Drug Discovery;Jul2011, Vol. 10 Issue 7, p479 

    The article focuses on advancements on various drugs for treating cystic fibrosis which are ready for regulatory submission. It mentions the VX-770 from Vertex Pharmaceuticals Inc. which was shown to have the ability to open up the cystic fibrosis transmembrane conductance regulator (CFTR) to...

  • New drug hits root of cystic fibrosis. Coghlan, Andy // New Scientist;3/5/2011, Vol. 209 Issue 2802, p18 

    The article looks at VX-770, an experimental drug developed by Vertex Pharmaceuticals which treats defects in a protein which causes cystic fibrosis. The drug works by correcting problems with the cystic fibrosis transmembrane regulator (CFTR), which forms channels for the movement of chloride...

  • Vertex and Cystic Fibrosis Foundation Therapeutics to Collaborate on Discovery and Development of New Medicines to Treat the Underlying Cause of Cystic Fibrosis.  // Biomedical Market Newsletter;5/14/2011, p806 

    The article presents information on the collaboration between Vertex Pharmaceuticals Inc., and Cystic Fibrosis Foundation Therapeutics Inc., regarding the continued discovery and development of correctors. Correctors refer to medicines, which aim to treat the underlying cause of cystic fibrosis....

  • CF Patient Power Fuels Early Kalydeco Approval. Serebrov, Mari // BioWorld Insight;2/13/2012, Vol. 20 Issue 7, p3 

    The article presents information on early approval of a new drug named as Kalydeco developed by the cystic fibrosis team of Vertex Pharmaceuticals Inc. It is stated that the company harnessed the power and experience of various cystic fibrosis patients for the development of this drug which is...

  • Kalydeco for Cystic Fibrosis.  // MPR - Pharmacist's Edition;Spring2012, Vol. 6 Issue 1, pA:6 

    The article offers brief information on Kalydeco, an ivacaftor tablet indicated for cystic fibrosis, from Vertex Pharmaceuticals Inc.

  • First 'breakthrough' drugs designated, but dilution worries linger. Dolgin, Elie // Nature Medicine;Feb2013, Vol. 19 Issue 2, p116 

    The article focuses on the benefits of and concerns over the U.S. Food and Drug Administration (FDA)'s new rule which speeds up market authorization of new drugs by designating them breakthrough therapy. It mentions that Vertex Pharmaceuticals Inc. has received the FDA approval for its cystic...

  • Vertex Cuts 370 Jobs on Incivek Sales Drop; Hitches Wagon to CF. Powers, Marie // BioWorld Today;10/30/2013, Vol. 24 Issue 209, p1 

    The article reports that Vertex Pharmaceuticals has slashed 370 jobs, 15 percent of its work force, due to sales drop of Incivex, a hepatitis C virus (HCV) drug. It states that revenue from Incivex dropped due to newer therapies to 85.6 million U.S. dollars in the third quarter of 2013 from...

  • Vertex Continues on a Roll, Adds $442M for Telapravir. Hollingsworth, Catherine // BioWorld Today;12/4/2009, Vol. 20 Issue 233, p1 

    The article reports on the planned stock sale of Vertex Pharmaceuticals designed to raise 442.8 million U.S. dollars. It relates the number of shares of stock that the Cambridge, Massachusetts-based company has agreed to sell. The offering is priced at 38.50 U.S. dollar per share. Proceeds from...

Share

Read the Article

Courtesy of VIRGINIA BEACH PUBLIC LIBRARY AND SYSTEM

Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics